1 40 1 Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Treatment of Symptoms in Children with Q3 Conditions Scoping Review Results Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. URL Address <a href="http://doi.org/10.1016/j.pediatrneurol.2011.02.001" target="_blank" rel="noreferrer noopener">http://doi.org/​10.1016/j.pediatrneurol.2011.02.001</a> Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Prolonged-release melatonin for children with neurodevelopmental disorders Publisher An entity responsible for making the resource available Pediatric Neurology Date A point or period of time associated with an event in the lifecycle of the resource 2011 Subject The topic of the resource sleep disturbance/disorders; Rett syndrome; pharmacologic intervention; prolonged-release melatonin; PR melatonin; melatonin Creator An entity primarily responsible for making the resource De Leersnyder H; Zisapel N; Laudon M Description An account of the resource Previous studies demonstrated the efficacy and safety of prolonged-release melatonin in children and adolescents with neurodevelopmental and behavioral disorders. The long-term effectiveness and safety of prolonged-release melatonin treatment were assessed in 88 children (42 girls and 46 boys) with neurodevelopmental disorders. These patients participated in a compassionate-use program with the drug Circadin (2 mg; Neurim Pharmaceuticals, Tel Aviv, Israel) in France, and received treatment in the context of regular care by a specialized physician. The study involved a structured questionnaire for the parents, comprising a combination of multiple-choice and numeric questions addressing sleep onset/offset, sleep quality problems, and mood. The dose of melatonin ranged from 4-6 mg, and treatment duration ranged from 6-72 months. Within 3 months, sleep latency with prolonged-release melatonin decreased by 44.0% (P < 0.001), sleep duration increased by 10.1% (P < 0.001), the number of awakenings decreased by 75% (P < 0.001), and sleep quality improved by 75%, compared with baseline (P < 0.001). No serious adverse events or treatment-related comorbidities were reported. Prolonged-release melatonin remains a safe, effective therapy for the long-term treatment of sleep disorders in children with neurodevelopmental disorders. © 2011 Elsevier Inc. All rights reserved. Identifier An unambiguous reference to the resource within a given context <a href="http://doi.org/10.1016/j.pediatrneurol.2011.02.001" target="_blank" rel="noreferrer noopener">10.1016/j.pediatrneurol.2011.02.001</a> Rights Information about rights held in and over the resource Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s). 2011 De Leersnyder H Laudon M melatonin Pediatric Neurology pharmacologic intervention PR melatonin prolonged-release melatonin Rett syndrome sleep disturbance/disorders Zisapel N